Chronic Malignancies Working Party

CLL & PCD & CAR-T PCD

Chair: Donal McLornan

Secretaries: Joanna Drozd-Sokolowska & Kavita Raj

Data management: Linda Koster, Laurien Baaij, Joe Tuffnell

Statisticians: Dirk-Jan Eikema, Luuk Gras, Simona Iacobelli

Subcommittee Chronic Lymphocytic Leukemia (CLL)

Chair: Olivier Tournilhac, Vice-chair: Michel van Gelder

Number of first allogeneic transplants for CLL registered at EBMT per year



Ongoing studies

Allogeneic transplantation for CLL – *Olivier Tournilhac and Michel van Gelder*

- AlloSCT after Multiple PI (AMPI).
- AlloSCT after stopping Ibrutinib for intolerance or relapse (ASTIIR).
- Venetoclax before and after alloSCT for CLL (VenAC).

Autologous and allogeneic HSCT for Richter's Syndrome (2008-2018) – *Romain Guièze*

The prognosis of Richter's syndrome (RS) is very poor as a result of and resistance to salvage treatment and overall survival following Richter transformation is usually less than 1 year. In this context, both autologous and allogeneic transplantation are strategies that have been proposed and even recommended in consolidation when remission can be achieved. We propose to analyze transplantation in Richter syndrome, with the hope of determining prognostic factors predictive of evolution. We believe that this study is important given the recent development of BCRi and BCL2i, and the emergence of Richter syndromes in this context.

Upcoming manuscript

T-cell prolymphocytic leukemia: autologous transplantation – *Joanna Drozd-Sokołowska*

T-cell prolymphocytic leukemia is a rare entity with poor prognosis. While alemtuzumab administered intravenously is considered a golden standard first line, yielding response in >90% patients, there is a strong need for both remission consolidation and effective treatment of relapse. There are some studies reporting on allogeneic HSCT for these indications. Although ASCT might not provide a cure to T-PLL patients, it might be a viable option for older, less fit patients. The aim of this study is to evaluate the outcomes of T-PLL patients receiving autoSCT.

Oral Session 19: Lymphoma and CLL – Wednesday April 26th , 2023, 12:30 – 13:45

Location: Room 241

12:48 – 12:57 OS19-03 Consolidation of response with Autologous Hematopoietic Cell Transplantation for T-cell Prolymphocytic Leukemia. Retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT - *Joanna Drozd-Sokolowska*

Most recent publications

Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience - *D. Chihara et al. Haematologica. 2022 Dec 22. doi: 10.3324/haematol.2022.281754*

Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT – *N. Polverelli et al. Lancet Haematol. 2023 Jan;10(1):e59-e70. doi: 10.1016/S2352-3026(22)00330-1*

Allogeneic hematopoietic cell transplantation in patients with CML chronic phase in the era of third generation tyrosine kinase inhibitors: a retrospective study by the Chronic Malignancies Working Party of the EBMT – *Y. Chalandon et al. Am J Hematol. 2023 Jan;98(1):112-121. doi: 10.1002/ajh.26764*

Outcomes after Allogeneic Hematopoietic Cell Transplant in patients diagnosed with Blast Phase of Myeloproliferative Neoplasms: a retrospective study from the Chronic Malignancies Working Party of the EBMT – *G. Ortí et al. Am J Hematol. 2023 Apr;98(4):628-638. doi: 10.1002/ajh.26833.*

Safety and Efficacy of Autologous Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients – The DIADEM Study from the Chronic Malignancies Working Party of the EBMT – *A. Waszczuk-Gajda et al. Bone Marrow Transplant. 2023 Jan 21. doi: 10.1038/s41409-023-01915-7*

Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable – a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT – *J. Drozd-Sokolowska et al. Bone Marrow Transplant. 2023 Feb;58(2):222-225. doi: 10.1038/s41409-022-01870-9*

Primary Cancer Matters in Therapy-related Myeloid Neoplasm Patients Receiving Allogeneic Hematopoietic Cell Transplantation: A Study From the Chronic Malignancies Working Party of the EBMT – *M. Robin et al. Hemasphere. 2023 Mar 3;7(4):e851. doi: 10.1097/HS9.0000000000000851*

The European landscape on allogeneic haematopoeietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: a perspective from the Chronic Malignancies Working Party of the EBMT - *O. Tournilhac et al. Bone Marrow Transplant. 2023. In press*

Subcommittee Plasma Cell Disorders (PCD)

Chair: Patrick Hayden, Vice-chair: Meral Beksaç , Vice-chair: Stefan Schönland

Number of first allogeneic transplants for MM registered by EBMT per year



Number of autologous transplants for MM registered by EBMT per year



Posters

P105 Autologous Peripheral Blood Stem Cell Mobilisation Techniques, Cell Yields and Practice Variation-By-Country in Myeloma Patients undergoing First Autologous Stem Cell Transplants in EBMT centres (2012-2021) - *Patrick Hayden*

P801 Long Term Outcomes Following Autologous Stem Cell Transplantation For Light Chain Deposition Disease: A Retrospective Study On Behalf Of The CMWP Of The EBMT - *Laurent Garderet*

P802 International Differences In Baseline Characteristics And Practice Patterns In Patients With Newly Diagnosed Multiple Myeloma Undergoing Upfront Autologous Stem Cell Transplantation - *Laurent Garderet*

P803 Worldwide Network For Blood And Marrow Transplantation global study on baseline characteristics/clinical outcomes in Multiple Myeloma Patients undergoing ASCT, a study off 61,725 patients - *Laurent Garderet*

Subcommittee CAR-T PCD

Chair: Nico Gagelmann, Vice-chair: Laurent Garderet

Number of CAR-T for MM registered at EBMT per year



Recent publication

Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper – *N. Gagelmann et al. The Lancet Heamatology. 2022 Oct;9(10):e786-e795. doi: 10.1016/S2352-3026(22)00226-5.*

Ongoing

Transplant versus CAR-T cell therapy for relapsed multiple myeloma: a joint study from the CMWP & CTIWP-EBMT – *Nico Gagelmann & Laurent Garderet*

Educational Meeting on Immunology and Cellular Therapy in Plasma Cell Disorders

24 November 2023 - 26 November 2023, Hamburg, Germany

On behalf of the Scientific Committee, we are pleased to invite you to the 1st Joint Educational Meeting of the Chronic Malignancies Working Party (CMWP) and the Cellular Therapy and Immunobiology Working Party (CTIWP) of the EBMT. This event will present the most recent advances and new perspectives in the field of immunology and cellular therapy for multiple myeloma and plasma disorders, including current practical challenges and new patient-centered perspectives.